Corvus Pharmaceuticals (FRA:C17) Tariff Resilience Score: 8/10 (As of Jul. 09, 2026)


FRA:C17 Corvus Pharmaceuticals Inc FRA:C17
34 GF Score
Price €13.27
! 1 Warning Sign
View Full Analysis

What is Corvus Pharmaceuticals Tariff Resilience Score?

Corvus Pharmaceuticals FRA:C17 +3.07% 34 Tariff Resilience Score is 8 as of Jul. 09, 2026. GuruFocus rates FRA:C17 with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,368 Biotechnology companies, Corvus Pharmaceuticals ranks better than 98.68% on this metric.

Corvus Pharmaceuticals has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Corvus Pharmaceuticals has Corvus Pharmaceuticals primarily operates within the US, with limited international supply chain dependencies. The company has not been significantly impacted by past tariffs and has strategies to mitigate potential risks.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Corvus Pharmaceuticals might have Highly Resilient.

Corvus Pharmaceuticals  (FRA:C17) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Corvus Pharmaceuticals Tariff Resilience Score Related Terms

FRA:C17 vs LXRX, CGEM, WVE: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Corvus Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corvus Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Corvus Pharmaceuticals's Tariff Resilience Score falls into.


FRA:C17
34GF Score
Corvus Pharmaceuticals Inc FRA:C17
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Corvus Pharmaceuticals (FRA:C17) has a Tariff Resilience Score of 8 as of Jul. 09, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Corvus Pharmaceuticals ranks #18 out of 1368 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Corvus Pharmaceuticals' Tariff Resilience Score too high?
Corvus Pharmaceuticals' current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Corvus Pharmaceuticals' value of 8 is 100% above this industry median. Based on the distribution chart, Corvus Pharmaceuticals ranks #18 out of 1368 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Corvus Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Corvus Pharmaceuticals' Tariff Resilience Score compare to LXRX and CGEM?
According to the Biotechnology industry distribution chart, Corvus Pharmaceuticals ranks #18 out of 1368 companies for Tariff Resilience Score. This places Corvus Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Corvus Pharmaceuticals' value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,368 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corvus Pharmaceuticals's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corvus Pharmaceuticals's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corvus Pharmaceuticals stock overvalued right now?
Corvus Pharmaceuticals (FRA:C17) has a current Tariff Resilience Score of 8. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Corvus Pharmaceuticals' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Corvus Pharmaceuticals (FRA:C17), the current Tariff Resilience Score is 8 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corvus Pharmaceuticals Business Description

Other Exchanges CRVS:USAC17:Germany
Address 901 Gateway Boulevard, Third Floor, South San Francisco, CA, USA, 94080
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
34GF Score

Get the complete analysis for FRA:C17

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.27
Price